Abstract Library

#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients

Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Genus T

Authors: Genus T, Bouvier C, Wong K, Srirajaskanthan R, Rous B,

Keywords: Neuroendocrine cancer, second primary, metachronous,

#1848 Liver Metastatic Disease (LMD) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Incidence, Treatment and Survival in a Multicenter Study in Argentina. Preliminary Report. ARGENTUM GROUP

Introduction: The first observational Study from our Group in Argentina, showed 60% incidence of liver mets at initial diagnosis. The treatment encompasses a wide scope of surgical and non-surgical modalities.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: O´Connor J

Authors: O'Connor J, Sanchez Loria F, Fauda M, Montal S, Podestá G,

Keywords: Liver, NETs,

#1846 Metachronous Pancreatic Neuroendocrine Tumors. An Unusual Interesting Case Report

Introduction: Literature surveillance state that in multiple endocrine neoplasia (MEN) disease, frequently occur, synchronous or metachronous neuroendocrine tumors (NETs) but in non-MEN patients are extremely rare.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Vaslamatzis M, Alevizopoulos N, Tegos T, Argyrakos T,

Keywords: pancreatic,

#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lepage C

Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,

Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,

#1209 Pancreatic Neuroendocrine Incidentalomas: When is Surgery in the Patient’s Best Interests?

Introduction: Small PNETs, many of which are diagnosed incidentally, pose a management dilemma. Whilst resection offers curative outcomes, the risks of surgery have led many to adopt surveillance strategies. 2cm is often used as a threshold for malignancy, but reports suggest that this value may not be valid.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Mills L, Ramage J, Prachalias A, Srinivasan P, Menon K,

Keywords: PNET,